A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer (EMBOLD-SCLC-303)
A Phase 3 Randomized Open-Label Study to Evaluate the Safety and Efficacy of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Newly Diagnosed Extensive Stage Small Cell Lung Cancer
Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive type of lung cancer. Current treatment options are limited, and response to treatment may not last long. Outcomes are especially poor when the cancer has spread to the brain. This study tests whether a new treatment: risvutatug rezetecan (Ris-Rez) with atezolizumab works better than standard of care treatment. Ris-Rez is designed to deliver cancer-killing medicine directly to cancer cells. Atezolizumab helps the immune system attack cancer cells. Researchers will see if this combination helps people live longer and keeps the cancer from getting worse.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
Undersøgelse Kontakt Backup
- Navn: EU GSK Clinical Trials Call Center
- Telefonnummer: +44 (0) 20 89904466
- E-mail: GSKClinicalSupportHD@gsk.com
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Is at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the informed consent form (ICF).
- Has histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC) at initial diagnosis and at trial entry and has received no prior systemic therapies for SCLC, with 1 exception where participants who have received one cycle of etoposide and carboplatin with or without atezolizumab are eligible
- Is capable of giving signed informed consent including compliance with the requirements and restrictions listed in the ICF and protocol.
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Has adequate organ function.
Exclusion Criteria:
- Has symptomatic central nervous system (CNS) metastases, CNS metastases with hemorrhagic features, or leptomeningeal disease.
- Has known allergy or hypersensitivity to study intervention components or excipients.
- Has any evidence of current interstitial lung disease or non-infectious pneumonitis or a prior history of interstitial lung disease (ILD) or non-infectious pneumonitis requiring high dose steroids or suspected ILD/non-infectious pneumonitis that cannot be ruled out by imaging.
- Has moderate to severe pulmonary disease or current clinically significant pulmonary compromise that, in the investigator's judgment, could jeopardize safety or study conduct.
- Has clinically significant bleeding symptoms, bleeding tumors, or significant bleeding tendency within 1 month prior to first dose.
- Known active infectious diseases requiring systemic treatment or known human immunodeficiency virus (HIV).
- Has received any prior systemic anticancer treatment for the disease under study.
- Has received any prior therapy with a Topoisomerase-1 (TOP1i), including antibody-drug conjugates that are effectively loaded as TOP1i, or treatment targeting B7-H3.
- Has severe, uncontrolled, or active cardiovascular disorders.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Ris-Rez + atezolizumab
|
Ris-Rez will be administered. Atezolizumab will be administered. |
|
Aktiv komparator: Etoposide, carboplatin, atezolizumab ± lurbinectedin
Participants will receive etoposide, carboplatin, atezolizumab with or without lurbinectedin. |
Carboplatin will be administered. Atezolizumab will be administered. Etoposide will be administered. Lurbinectedin will be administered. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall survival (OS)
Tidsramme: Up to 50 months
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Up to 50 months
|
|
Progression-free survival (PFS) by Blinded independent central review (BICR) assessment
Tidsramme: Up to 50 months
|
PFS is defined as the time from the date of randomization to the date of first documented objective tumor progression per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by BICR assessment or death from any cause, whichever occurs first. |
Up to 50 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to confirmed deterioration of disease-related symptoms and physical functioning
Tidsramme: Up to 63 months
|
Time from the date of randomization to the first confirmed clinically meaningful deterioration in disease related symptoms and physical functioning using validated questionnaires will be measured. |
Up to 63 months
|
|
Brain PFS
Tidsramme: Up to 63 months
|
Brain PFS is defined as the time from the date of randomization to the date of first documented brain disease progression (PD) per modified Response assessment in neuro-oncology brain metastases (RANO-BM) by BICR assessment or death from any cause, whichever occurs first in participants with a presence of brain metastases at baseline. |
Up to 63 months
|
|
PFS by Investigator Assessment
Tidsramme: Up to 63 months
|
PFS is defined as the time from the date of randomization to the date of first documented PD per RECIST 1.1 by investigator assessment or death from any cause, whichever occurs first. |
Up to 63 months
|
|
Objective response rate (ORR)
Tidsramme: Up to 63 months
|
ORR is defined as the percentage of participants with best overall confirmed response of either complete response (CR) or partial response (PR) per RECIST 1.1 by RECIST-BICR assessment. |
Up to 63 months
|
|
Duration of response (DOR)
Tidsramme: Up to 63 months
|
DOR is defined as the time from the date of first documented objective response (CR or PR) that is subsequently confirmed per RECIST 1.1 by RECIST-BICR assessment to the date of first documented PD per RECIST 1.1 by BICR assessment or death due to any cause, whichever occurs first. |
Up to 63 months
|
|
ORR for participants not receiving bridging cycle
Tidsramme: Up to 63 months
|
ORR is defined as the percentage of participants with best overall confirmed response of either CR or PR per RECIST 1.1 by RECIST-BICR assessment |
Up to 63 months
|
|
DOR for participants not receiving bridging cycle
Tidsramme: Up to 63 months
|
DOR is defined as the time from the date of first documented objective response (CR or PR) that is subsequently confirmed per RECIST 1.1 by RECIST-BICR assessment to the date of first documented PD per RECIST 1.1 by BICR assessment or death due to any cause, whichever occurs first. |
Up to 63 months
|
|
Participant reported experience on study treatment
Tidsramme: Up to 63 months
|
Number of participants who reported their experience with study treatment using validated questionnaires will be measured. |
Up to 63 months
|
|
Time to worsening of participants overall quality of life
Tidsramme: Up to 63 months
|
Time from the date of randomization to the first confirmed clinically meaningful deterioration in overall quality of life using validated questionnaires will be measured. |
Up to 63 months
|
|
Number of participants with adverse events (AEs), serious adverse events (SAEs), adverse events of special interest (AESIs) by severity
Tidsramme: Up to 63 months
|
Up to 63 months
|
|
|
Number of participants with AEs leading to dose modifications or study intervention discontinuation
Tidsramme: Up to 63 months
|
Up to 63 months
|
|
|
Number of participants with changes in hematology parameters
Tidsramme: Up to 63 months
|
Up to 63 months
|
|
|
Observed pharmacokinetic concentration of Ris-Rez
Tidsramme: Up to 63 months
|
Up to 63 months
|
|
|
Number of participants with Antidrug antibody (ADA) and Neutralizing Antibody (NAb) against Ris-Rez
Tidsramme: Up to 63 months
|
Up to 63 months
|
|
|
Titres of ADA against Ris-Rez
Tidsramme: Up to 63 months
|
Up to 63 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: GSK Clinical Trials, GlaxoSmithKline
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Luftvejssygdomme
- Lungesygdomme
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Lungeneoplasmer
- Småcellet lungekarcinom
- Organiske kemikalier
- Kulbrinter
- Kulbrinter, cyklisk
- Kulhydrater
- Podophyllotoxin
- Tetrahydronaphthalenes
- Naphthalenes
- Polycykliske aromatiske kulbrinter
- Kulbrinter, aromatisk
- Polycykliske forbindelser
- Glukosider
- Glycosider
- Koordinationskomplekser
- Etoposid
- Carboplatin
- PM 01183
- atezolizumab
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 300599
- 2026-527806-19 (Anden identifikator: EU CT Number)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
IPD-delingstidsramme
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
IPD-delingsadgangskriterier
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .